G
Gemma Biotherapeutics
Accelerating global access to advanced gene therapies for rare diseases through innovative research and international coalitions
About Gemma Biotherapeutics
GEMMABio is a therapeutics company focused on accelerating the research and global accessibility of advanced gene therapies for rare diseases. The company collaborates with international coalitions and operates alongside Franklin Biolabs to expedite the development and delivery of life-changing treatments. GEMMABio's business model is centered around research and innovation, aiming to bring new gene therapies to market faster. The company generates revenue through the commercialization of its gene therapy platforms, which include three FDA-approved AAV-based gene therapies and numerous active programs in development. GEMMABio serves patients suffering from rare diseases, providing them with cutting-edge treatments that are otherwise unavailable. The market it operates in is the biotechnology and gene therapy sector, which is highly specialized and rapidly evolving. The company's success is driven by its extensive patent portfolio and its ability to bring new therapies from the bench to the bedside efficiently.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jul 2026 | $0 | — | Advanced Research Projects Agency for Health - ARPA-H | ↗ |
| SEED✓Equity / VC | Dec 2024 | $34M | $136M | Bioluminescence Ventures · Earlybird Venture Capital · Double Point Ventures | ↗ |
Growth signals
Latest recorded traffic for Gemma Biotherapeutics is 5.1K monthly website visits, up 264.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Gemma Biotherapeutics in the Philadelphia ecosystem
The Gemma Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Fiocruz
Bioluminescence Ventures
Earlybird Venture Capital
Double Point Ventures
Advanced Research Projects Agency for Health - ARPA-H
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gemma Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gemma Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










